Leerink Partnrs Comments on Kyverna Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:KYTX)

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Analysts at Leerink Partnrs lowered their Q1 2024 earnings per share estimates for Kyverna Therapeutics in a note issued to investors on Wednesday, March 27th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($1.20) for the quarter, down from their previous forecast of ($0.82). Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.16) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.99) EPS and FY2024 earnings at ($3.48) EPS.

Several other equities research analysts also recently weighed in on the company. SVB Leerink initiated coverage on Kyverna Therapeutics in a report on Monday, March 4th. They set an “outperform” rating and a $48.00 price target for the company. JPMorgan Chase & Co. began coverage on Kyverna Therapeutics in a research report on Monday, March 4th. They issued an “overweight” rating and a $39.00 price objective for the company. Wells Fargo & Company began coverage on Kyverna Therapeutics in a research report on Monday, March 4th. They issued an “overweight” rating and a $44.00 price objective for the company. Finally, Morgan Stanley began coverage on Kyverna Therapeutics in a research report on Monday, March 4th. They issued an “overweight” rating and a $40.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $42.75.

Kyverna Therapeutics Trading Up 3.0 %

Shares of NASDAQ KYTX opened at $24.84 on Friday. Kyverna Therapeutics has a 1-year low of $23.12 and a 1-year high of $35.06.

Insider Activity

In other news, major shareholder Northpond Ventures Iii Gp, Llc purchased 450,000 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was acquired at an average price of $22.00 per share, for a total transaction of $9,900,000.00. Following the completion of the transaction, the insider now directly owns 450,000 shares in the company, valued at approximately $9,900,000. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

About Kyverna Therapeutics

Kyverna Therapeutics Inc is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company’s lead product candidate includes KYV-101. Kyverna Therapeutics Inc is based in EMERYVILLE, Calif.